• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • UDI Now Proposed for All Class III Medical Devices and IVDs

UDI Now Proposed for All Class III Medical Devices and IVDs

Monday, 26 July 2021 / Published in Medical Device, News, NMPA Registration in China

UDI Now Proposed for All Class III Medical Devices and IVDs

On July 19, 2021, the NMPA (National Medical Products Administration) published a regulatory draft to solicit public comments on its proposal to require all class III medical devices and IVDs manufactured after March 1, 2022 to have unique device identifiers (UDI). This proposal follows a pilot plan implemented earlier this year requiring only that high-risk class III medical devices have UDIs.

Highlights

Following the implementation of the UDI for the first batch of products, the NMPA suggests the following:

  • For the second batch of medical devices manufactured after March 1, 2022, these are required to have their own UDI, however, the UDI will not be required for medical devices manufactured before March 1, 2022, subject to the manufacturing date indicated on the label.
  • The UDI of the product’s smallest (innermost) packaging unit should be submitted to the UDI registration system from March 1, 2022, onwards.
  • For the second batch of medical devices manufactured after March 1, 2022, the UDI of the product’s smallest (innermost) packaging unit should be uploaded to the UDI database already before selling into the market.

The public consultation is currently open until August 16, 2021.

By Jacky Li and Colleen Xu. Contact Cisema if you would like to learn more.

Tagged under: In vitro diagnostics, UDI, UDID, Unique Device Identification

What you can read next

Medical device QMS verification guidelines
Medical device QMS verification guidelines updated
New Clinical Trial Exemption List
China's Medical Device Classification Sodium Hyaluronate
China’s Medical Device Classification of Sodium Hyaluronate Products is Now Open for Comments

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP